Fingolimod-associated Balo's Concentric Sclerosis in Multiple Sclerosis: A Case Report

Overview

Journal Clin Case Rep

Date 2024 Aug 7

PMID 39109309

Authors

Parisa Sharifi

Amir Moradi

Abdorreza Naser Moghadasi

Affiliations

Soon will be listed here.

Abstract

A report of Balo's concentric sclerosis developed alongside with fingolimod use in a patient with previously diagnosed multiple sclerosis.

References

Gavito-Higuera J, Mullins C, Ramos-Duran L, Olivas Chacon C, Hakim N, Palacios E . Fungal Infections of the Central Nervous System: A Pictorial Review. J Clin Imaging Sci. 2016; 6:24. PMC: 4926551. DOI: 10.4103/2156-7514.184244. View

Koudriavtseva T, Lorenzano S . A possible role of impaired cell-mediated immunity in the pathogenesis of tumefactive demyelinating lesions. Mult Scler Relat Disord. 2017; 18:184-185. DOI: 10.1016/j.msard.2017.10.006. View

Ongphichetmetha T, Aungsumart S, Siritho S, Apiwattanakul M, Tanboon J, Rattanathamsakul N . Tumefactive demyelinating lesions: a retrospective cohort study in Thailand. Sci Rep. 2024; 14(1):1426. PMC: 10791607. DOI: 10.1038/s41598-024-52048-w. View

Pilz G, Harrer A, Wipfler P, Oppermann K, Sellner J, Fazekas F . Tumefactive MS lesions under fingolimod: a case report and literature review. Neurology. 2013; 81(19):1654-8. DOI: 10.1212/01.wnl.0000435293.34351.11. View

Jolliffe E, Guo Y, Hardy T, Morris P, Flanagan E, Lucchinetti C . Clinical and Radiologic Features, Pathology, and Treatment of Baló Concentric Sclerosis. Neurology. 2021; 97(4):e414-e422. PMC: 8362356. DOI: 10.1212/WNL.0000000000012230. View

Ward M, Jones D, Goldman M . Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis. Expert Opin Drug Saf. 2014; 13(7):989-98. DOI: 10.1517/14740338.2014.920820. View

Calabresi P, Radue E, Goodin D, Jeffery D, Rammohan K, Reder A . Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014; 13(6):545-56. DOI: 10.1016/S1474-4422(14)70049-3. View

Tzanetakos D, Vakrakou A, Tzartos J, Velonakis G, Evangelopoulos M, Anagnostouli M . Heterogeneity of Baló's concentric sclerosis: a study of eight cases with different therapeutic concepts. BMC Neurol. 2020; 20(1):400. PMC: 7604966. DOI: 10.1186/s12883-020-01971-2. View

Hall W . Infectious lesions of the brain stem. Neurosurg Clin N Am. 1993; 4(3):543-51. View

10.

Algahtani H, Shirah B, Alassiri A . Tumefactive demyelinating lesions: A comprehensive review. Mult Scler Relat Disord. 2017; 14:72-79. DOI: 10.1016/j.msard.2017.04.003. View

11.

Nakayama M, Naganawa S, Ouyang M, Jones K, Kim J, Capizzano A . A Review of Clinical and Imaging Findings in Tumefactive Demyelination. AJR Am J Roentgenol. 2021; 217(1):186-197. DOI: 10.2214/AJR.20.23226. View

12.

Seewann A, Enzinger C, Filippi M, Barkhof F, Rovira A, Gass A . MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain : A review of reported findings. J Neurol. 2007; 255(1):1-10. DOI: 10.1007/s00415-007-0754-x. View

13.

Hardy T, Reddel S, Barnett M, Palace J, Lucchinetti C, Weinshenker B . Atypical inflammatory demyelinating syndromes of the CNS. Lancet Neurol. 2016; 15(9):967-981. DOI: 10.1016/S1474-4422(16)30043-6. View

14.

Kappos L, Cohen J, Collins W, de Vera A, Zhang-Auberson L, Ritter S . Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings. Mult Scler Relat Disord. 2015; 3(4):494-504. DOI: 10.1016/j.msard.2014.03.002. View

15.

Kania K, Ambrosius W, Kozubski W, Kalinowska A . Case Report: Baló's Concentric Sclerosis-Like Lesion in a Patient With Relapsing-Remitting Multiple Sclerosis Treated With Dimethyl Fumarate. Front Neurol. 2022; 13:891113. PMC: 9168072. DOI: 10.3389/fneur.2022.891113. View

16.

Karaarslan E, Altintas A, Senol U, Yeni N, Dincer A, Bayindir C . Baló's concentric sclerosis: clinical and radiologic features of five cases. AJNR Am J Neuroradiol. 2001; 22(7):1362-7. PMC: 7975204. View

17.

Hauser S, Cree B . Treatment of Multiple Sclerosis: A Review. Am J Med. 2020; 133(12):1380-1390.e2. PMC: 7704606. DOI: 10.1016/j.amjmed.2020.05.049. View

18.

Chun J, Brinkmann V . A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov Med. 2011; 12(64):213-28. PMC: 3694567. View

19.

MOORE G, Neumann P, Suzuki K, Lijtmaer H, Traugott U, Raine C . Balo's concentric sclerosis: new observations on lesion development. Ann Neurol. 1985; 17(6):604-11. DOI: 10.1002/ana.410170614. View

20.

Rosciszewska-Zukowska I, Galiniak S, Bartosik-Psujek H . Clinical Characteristics of Headache in Multiple Sclerosis Patients: A Cross-Sectional Study. J Clin Med. 2023; 12(10). PMC: 10219221. DOI: 10.3390/jcm12103518. View